Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment
Authors:
Open Access
- 23 October 2026
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic DiseasesArthritis & Rheumatology, 2024
- EphB2 Receptor Promotes Dermal Fibrosis in Systemic SclerosisArthritis & Rheumatology, 2024
- Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular SignaturesArthritis & Rheumatology, 2024
- A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusArthritis & Rheumatology, 2022
- Profibrotic Activation of Human Macrophages in Systemic SclerosisArthritis & Rheumatology, 2020
- Belimumab for the Treatment of Early Diffuse Systemic SclerosisArthritis & Rheumatology, 2017
- Platelets Induce Thymic Stromal Lymphopoietin Production by Endothelial Cells: Contribution to Fibrosis in Human Systemic SclerosisArthritis & Rheumatology, 2016
- Review: Evidence That Systemic Sclerosis Is a Vascular DiseaseArthritis & Rheumatism, 2013
- JAK‐2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosisArthritis & Rheumatism, 2012
- Increased interleukin-17 production in patients with systemic sclerosisArthritis & Rheumatism, 2000